Sagar Lonial, MD

Sagar Lonial, MD, a professor and Chair of the Department of Hematology and Medical Oncology at Emory University School of Medicine, and the chief medical officer of Winship Cancer Institute of Emory University, explains the need for transplant in patients with multiple myeloma.

Sagar Lonial, MD, discusses how phase III trials should be designed in the United States for patients with multiple myeloma in the early-relapse setting.

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses the results from 2 large phase III trials presented earlier this year for triplet regimens including pomalidomide in multiple myeloma.

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses the importance of partnering with a myeloma center when managing multiple myeloma.

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses CAR T-cell therapy for myeloma and other hematologic malignancies.

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses recent advancements in the treatment paradigm for multiple myeloma.

Sagar Lonial, MD, discusses an ongoing phase III trial investigating if any interventions would change the natural history of smoldering myeloma.

Sagar Lonial, MD, professor, School of Medicine, executive vice chair, Department of Hematology & Medical Oncology, chief medical officer, Winship Cancer Institute, Emory University, discusses whether or not to treat patients with smoldering multiple myeloma (SMM), or asymptomatic myeloma.

Sagar Lonial, MD, professor, School of Medicine, executive vice chair, Department of Hematology & Medical Oncology, chief medical officer, Winship Cancer Institute, Emory University, discusses the ELOQUENT-2 study in patients with relapsed/refractory multiple myeloma.